Richard Delorme is head of the Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders (InovAND) and head of the Department of Child and Adolescent Psychiatry at the Robert Debré Hospital, both in Paris, France. He has a broad background in child psychiatry and genetics, with expertise in the identification of biomarkers in rare diseases associated with autism. He is also a researcher at the Human Genetics and Cognitive Functions Laboratory at the Institut Pasteur, in Paris. In recent years, he has been involved in several research programs, brain imaging studies and IPSC-based drug screening technology. He is an author on more than 100 publications.
Richard Delorme
Head
Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders
From this contributor
Coronavirus tool kit may aid families with autistic children during lockdown
To help families cope with the sudden loss of professional support during the pandemic, one team in France has created a set of resources and information.
Coronavirus tool kit may aid families with autistic children during lockdown
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.